A5071855191- Polyomavirus and related diseases
- CAR-T cell therapy research
- Virus-based gene therapy research
- Plant Virus Research Studies
- Chronic Lymphocytic Leukemia Research
- Cytomegalovirus and herpesvirus research
- Bacteriophages and microbial interactions
- Monoclonal and Polyclonal Antibodies Research
- Full-Duplex Wireless Communications
- Immunodeficiency and Autoimmune Disorders
- Mesenchymal stem cell research
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Microwave Engineering and Waveguides
- Hepatitis B Virus Studies
- Tissue Engineering and Regenerative Medicine
- Viral-associated cancers and disorders
- MicroRNA in disease regulation
- Cancer Cells and Metastasis
- Glycosylation and Glycoproteins Research
- Immune Response and Inflammation
- Energy Harvesting in Wireless Networks
- Animal Virus Infections Studies
- Antenna Design and Analysis
- Extracellular vesicles in disease
National Institute of Arthritis and Musculoskeletal and Skin Diseases
2020-2024
Atara Biotherapeutics (United States)
2021
Georgetown University
2017-2020
National Institutes of Health
2014-2020
National Heart Lung and Blood Institute
2016-2020
Georgetown University Medical Center
2017-2020
National Cancer Institute
2014-2020
Virus positive Merkel cell carcinoma (VP-MCC) is an aggressive but immunogenic skin malignancy driven by polyomavirus (MCPyV) T antigen (TAg). Since adoptive transfer (ACT) can be effective against virus-driven malignancies, we set out to develop a methodology for generating MCPyV TAg specific cells. common, asymptomatic infection and virus-exposed healthy donors represent potential source of cells ACT. were generated using monocyte-derived dendritic (moDCs) pulsed with peptide libraries...
Hairy cell leukemia (HCL) is a purine analog-responsive B-cell malignancy containing the BRAF V600E mutation, expressing CD22, CD11c, CD103, tartrate resistant acid phosphatase (TRAP) CD25, CD123, and annexin 1A. latter 4 markers are usually absent in more aggressive chemoresistant variant HCLv. To evaluate differences between HCL HCLv, expression microarrays comparing with HCLv were performed for 24694 genes using 47323 probes. Microarray data from 35 27 purified samples showed greatest...
<b>Abstract ID 96154</b> <b>Poster Board 257</b> Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with high case fatality rate. Currently, immune checkpoint inhibitors (ICI) are the first line of treatment for metastatic MCC, but 50% patients do not achieve durable responses. To identify novel treatments we screened 4,000 compounds their ability to reduce MCC viability. Using Area Under Dose-Response Curve, identified CDK as efficacious against multiple lines....
<h3>Background</h3> Mesothelin (MSLN) is a GPI-anchored membrane protein with high expression levels in an array of malignancies including mesothelioma and attractive target antigen for tumor surface antigen-targeting therapies. Regional administration autologous, 2nd generation MSLN-targeted CAR-T cells malignant pleural has shown promise early clinical evaluation.<sup>1 2</sup> More recently, next-generation MSLN-targeted, autologous CAR T therapy leveraging 1XX signaling PD1DNR currently...
Background: Reactivation of latent viruses in allogeneic stem cell transplant (SCT) recipients significantly increases the risk for non-relapse mortality. Ex vivo generated virus specific T cells can effectively treat infections post-SCT but they have not been tested as a prophylaxis early reactivation. Here Phase I 3 + dose escalation study we transferred multi-virus (MVSTs) immediately post SCT to prevent viral reactivation depleted sibling HLA-matched SCT. Methods: Subjects were eligible...
Abstract Classic hairy cell leukemia (HCLc) is a B-cell malignancy with distinctive immunophenotype, typically expressing CD20, CD22, CD25, CD11c, CD103, CD123, annexin A1, tartrate-resistant acid phosphatase (TRAP), and BRAF V600E mutation. Purine analog therapy highly effective complete remission rates of approximately 85% in first line. HCL variant (HCLv) recognized as distinct entity, lacking CD25 usually expression, also lacks the Patients respond poorly to purine analogs, partial...
Abstract Truncated large T (LT-T) and small (ST) antigens of Merkel Cell Polyomavirus (MCV) are viral oncoproteins critical for pathogenesis Carcinoma (MCC), making this malignancy an attractive target immunotherapy. We explored feasibility generating LT-T ST specific cells from 12 healthy donors 4 patients with MCC. Manufactured overlapping peptide libraries (pepmixes) spanning entire proteins were pulsed onto autologous dendritic or peripheral blood mononuclear co-cultured lymphocytes in...
Abstract Merkel Cell Carcinoma (MCC) is an aggressive skin tumor caused by Polyomavirus (MCV) in ~80% of cases that responds poorly to standard chemotherapies. Virus positive tumors have a low mutational burden, and are driven alternatively spliced T-antigens (TAG), small T (sT) truncated large antigen (LTT). These intracellular proteins constitutively expressed MCC required for survival. We hypothesized MCV TAG can be targeted cytotoxic lymphocytes potential use as adoptive cell...
Abstract Hematopoietic stem cell transplant (HCT) patients often risk complications from viral infection due to loss of protective antiviral immunity. One strategy overcome this hurdle is supplement the HCT with multi-virus specific T cells (MVST). In phase I trial (NCT02231853), MVSTs were generated using HLA-matched donor-derived dendritic pulsed overlapping peptide libraries (cytomegalovirus (CMV), Epstein-Barr virus, Adenovirus, and BK polyomavirus) then co-cultured donor lymphocytes....
Abstract Merkel Cell Carcinoma (MCC) is an aggressive neuroendocrine skin cancer that highly immunogenic. Approximately 80% of MCC tumors are virus positive (VP-MCC) and express cell polyomavirus (MCPyV) T antigens drive oncogenesis. As VP-MCC have a low mutation burden with few predicted neoantigens, viral oncogenes thought to be primary targets for anti-cancer immunity. Immune checkpoint inhibitors improve survival, yet not all patients durable responses. who fail inhibition or immune...